A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

被引：0
|
作者：
A H Ko
M A Tempero
Y-S Shan
W-C Su
Y-L Lin
E Dito
A Ong
Y-W Wang
C G Yeh
L-T Chen
机构：
[1] Comprehensive Cancer Center,Division of Hematology/Oncology
[2] University of California,Department of Surgery
[3] San Francisco,Department of Internal Medicine
[4] National Cheng Kung University Hospital,Department of Oncology
[5] National Cheng Kung University Hospital,Department of Internal Medicine and Cancer Center
[6] National Taiwan University Hospital,undefined
[7] PharmaEngine,undefined
[8] Inc.,undefined
[9] National Institute of Cancer Research,undefined
[10] National Health Research Institutes,undefined
[11] Kaohsiung Medical University Hospital,undefined
[12] Kaohsiung Medical University,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
Irinotecan sucrosofate; liposome; pancreatic cancer; second-line; gemcitabine-refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：920 / 925
页数：5
相关论文
共 50 条
  • [31] Phase I study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy in gemcitabine-refractory pancreatic cancer patients.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Ogura, T.
    Nakachi, K.
    Suzuki, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 272 - 273
  • [32] Phase II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Morizane, C.
    Okusaka, T.
    Ikeda, M.
    Furuse, J.
    Ohkawa, S.
    Nakachi, K.
    Suzuki, E.
    Ueno, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 388 - 388
  • [33] Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study
    Melisi, D.
    Melisi, D.
    Siveke, J. T.
    Blanc, J.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L.
    Becker, C.
    Mamlouk, K.
    De Jong, F.
    Hubner, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Morizane, Chigusa
    Okusaka, Takuji
    Ueno, Hideki
    Kondo, Shunsuke
    Ikeda, Masafumi
    Furuse, Junji
    Shinichi, Ohkawa
    Nakachi, Kohei
    Mitsunaga, Shuichi
    Kojima, Yasushi
    Suzuki, Eiichiro
    Ueno, Makoto
    Yamaguchi, Tomohiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 957 - 964
  • [35] Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [36] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Chigusa Morizane
    Takuji Okusaka
    Hideki Ueno
    Shunsuke Kondo
    Masafumi Ikeda
    Junji Furuse
    Ohkawa Shinichi
    Kohei Nakachi
    Shuichi Mitsunaga
    Yasushi Kojima
    Eiichiro Suzuki
    Makoto Ueno
    Tomohiro Yamaguchi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 957 - 964
  • [37] A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
    Imaoka, H.
    Sasaki, M.
    Ueno, M.
    Ozaka, M.
    Kobayashi, S.
    Fukushima, T.
    Furukawa, T.
    Ikeda, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1484 - S1484
  • [38] Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine
    Hubner, R.
    Cubillo, A.
    Blanc, J. -F.
    Melisi, D.
    Von Hoff, D.
    Wang-Gillam, A.
    Chen, L. -T.
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    De Jong, F.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 119 - 119
  • [40] Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients
    Kim, Hyun Jung
    Yun, Jina
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Tae Hoon
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Nam Su
    Moon, Jong Ho
    Park, Sang Heum
    Lee, Kyu Taek
    Park, Seong Kyu
    Won, Jong-Ho
    Park, Hee Sook
    Hong, Dae Sik
    ONCOLOGY LETTERS, 2012, 3 (06) : 1314 - 1318
12345